Neo Polycin Hc

Neomycin And Polymyxin B Sulfates, Bacitracin Zinc And Hydrocortisone Acetate


Padagis Us Llc
Human Prescription Drug
NDC 0574-4144
Neo Polycin Hc also known as Neomycin And Polymyxin B Sulfates, Bacitracin Zinc And Hydrocortisone Acetate is a human prescription drug labeled by 'Padagis Us Llc'. National Drug Code (NDC) number for Neo Polycin Hc is 0574-4144. This drug is available in dosage form of Ointment. The names of the active, medicinal ingredients in Neo Polycin Hc drug includes Bacitracin Zinc - 400 [USP'U]/g Hydrocortisone Acetate - 10 mg/g Neomycin Sulfate - 3.5 mg/g Polymyxin B Sulfate - 10000 [USP'U]/g . The currest status of Neo Polycin Hc drug is Active.

Drug Information:

Drug NDC: 0574-4144
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Neo Polycin Hc
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Neomycin And Polymyxin B Sulfates, Bacitracin Zinc And Hydrocortisone Acetate
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Padagis Us Llc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Ointment
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:BACITRACIN ZINC - 400 [USP'U]/g
HYDROCORTISONE ACETATE - 10 mg/g
NEOMYCIN SULFATE - 3.5 mg/g
POLYMYXIN B SULFATE - 10000 [USP'U]/g
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:OPHTHALMIC
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: ANDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 07 Jan, 2015
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 22 Jan, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: ANDA062166
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Padagis US LLC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:1116150
1116154
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0058552585520
UPC stands for Universal Product Code.
UNII:89Y4M234ES
3X7931PO74
057Y626693
19371312D4
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Aminoglycoside Antibacterial [EPC]
Aminoglycosides [CS]
Corticosteroid Hormone Receptor Agonists [MoA]
Corticosteroid [EPC]
Decreased Cell Wall Synthesis & Repair [PE]
Polymyxin-class Antibacterial [EPC]
Polymyxins [CS]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
0574-4144-351 TUBE in 1 CARTON (0574-4144-35) / 3.5 g in 1 TUBE07 Jan, 2015N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Neo polycin hc neomycin and polymyxin b sulfates, bacitracin zinc and hydrocortisone acetate neomycin sulfate neomycin polymyxin b sulfate polymyxin b bacitracin zinc bacitracin hydrocortisone acetate hydrocortisone petrolatum mineral oil

Indications and Usage:

Indications and usage: neo-polycin® hc ophthalmic ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (see clinical pharmacology: microbiology ). the particular anti-infective drugs in this product are
active against the following common bacterial eye pathogens: staphylococcus aureus, streptococci, including streptococcus pneumoniae, escherichia coli, haemophilus influenzae, klebsiella/enterobacter species , neisseria species , and pseudomonas aeruginosa . the product does not provide adequate coverage against serratia marcescens .

Warnings:

Warnings: not for injection into the eye. neomycin and polymyxin b sulfates, bacitracin zinc and hydrocortisone acetate ophthalmic ointment should never be directly introduced into the anterior chamber of the eye. ophthalmic ointments may retard corneal wound healing. prolonged use of corticosteroids may result in ocular hypertension and/or glaucoma, with damage to the optic nerve, defects in visual acuity and fields of vision, and in posterior subcapsular cataract formation. prolonged use may suppress the host immune response and thus increase the hazard of secondary ocular infections. various ocular diseases and long-term use of topical corticosteroids have been known to cause corneal and scleral thinning. use of topical corticosteroids in the presence of thin corneal or scleral tissue may lead to perforation. acute purulent infections of the eye may be masked or enhanced by the presence of corticosteroid medication. if these products are used for 10 days or longer, intraocular press
ure should be routinely monitored even though it may be difficult in uncooperative patients. corticosteroids should be used with caution in the presence of glaucoma. intraocular pressure should be checked frequently. the use of corticosteroids after cataract surgery may delay healing and increase the incidence of filtering blebs. use of the ocular corticosteroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). employment of corticosteroid medication in the treatment of herpes simplex requires great caution; frequent slit lamp microscopy is recommended. topical antibiotics, particularly neomycin sulfate, may cause cutaneous sensitization. a precise incidence of hypersensitivity reactions (primarily skin rash) due to topical antibiotics is not known. the manifestations of sensitization to topical antibiotics are usually itching, reddening, and edema of the conjunctiva and eyelid. a sensitization reaction may manifest simply as a failure to heal. during long-term use of topical antibiotic products, periodic examination for such signs is advisable, and the patient should be told to discontinue the product if they are observed. symptoms usually subside quickly on withdrawing the medication. applications of products containing these ingredients should be avoided for the patient thereafter (see precautions: general ).

General Precautions:

General: the initial prescription and renewal of the medication order beyond 8 grams should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining. if signs and symptoms fail to improve after two days, the patient should be re-evaluated. as fungal infections of the cornea are particularly prone to develop coincidentally with long-term corticosteroid applications, fungal invasion should be suspected in any persistent corneal ulceration where a corticosteroid has been used or is in use. fungal cultures should be taken when appropriate. if this product is used for 10 days or longer, intraocular pressure should be monitored (see warnings ). there have been reports of bacterial keratitis associated with the use of topical ophthalmic products in multiple-dose containers which have been inadvertently contaminated by patients, most of whom had a concurrent corneal disease or a disr
uption of the ocular epithelial surface (see precautions: information for patients ). allergic cross-reactions may occur which could prevent the use of any or all of the following antibiotics for the treatment of future infections: kanamycin, paromomycin, streptomycin, and possibly gentamicin.

Dosage and Administration:

Dosage and administration: apply the ointment in the affected eye every 3 or 4 hours, depending on the severity of the condition. not more than 8 grams should be prescribed initially and the prescription should not be refilled without further evaluation as outlined in precautions above.

Contraindications:

Contraindications: neo-polycin® hc ophthalmic ointment is contraindicated in most viral diseases of the cornea and conjunctiva including: epithelial herpes simplex keratitis (dendritic keratitis), vaccinia and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. neomycin and polymyxin b sulfates, bacitracin zinc and hydrocortisone acetate ophthalmic ointment is also contraindicated in individuals who have shown hypersensitivity to any of its components. hypersensitivity to the antibiotic component occurs at a higher rate than for other components.

Adverse Reactions:

Adverse reactions: adverse reactions have occurred with corticosteroid/anti-infective combination drugs which can be attributed to the corticosteroid component, the anti-infective component, or the combination. the exact incidence is not known. reactions occurring most often from the presence of the anti-infective ingredient are allergic sensitization reactions including itching, swelling, and conjunctival erythema (see warnings ). more serious hypersensitivity reactions, including anaphylaxis, have been reported rarely. the reactions due to the corticosteroid component in decreasing order of frequency are: elevation of intraocular pressure (iop) with possible development of glaucoma, and infrequent optic nerve damage; posterior subcapsular cataract formation; and delayed wound healing. secondary infection: the development of the secondary ocular infection has occurred after use of combinations containing corticosteroids and antimicrobials. fungal and viral infections of the cornea are
particularly prone to develop coincidentally with long-term applications of a corticosteroid. the possibility of fungal invasion must be considered in any persistent corneal ulceration where corticosteroid treatment has been used (see warnings). local irritation on installation has been reported. if signs and symptoms fail to improve after two days, the patient should be re-evaluated (see precautions). to report suspected adverse reactions, contact perrigo at 1-866-634-9120 or fda at 1-800-fda-1088 or www.fda.gov/medwatch.

Use in Pregnancy:

Pregnancy: teratorgenic effects: pregnancy category c. corticosteroids have been found to be teratogenic in rabbits when applied topically at concentrations of 0.5% on days 6 to 18 of gestation and in mice when applied topically at a concentration of 15% on days 10 to 13 of gestation. there are no adequate and well-controlled studies in pregnant women. neomycin and polymyxin b sulfates, bacitracin zinc and hydrocortisone acetate ophthalmic ointment should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Pediatric Use:

Pediatric use: safety and effectiveness in children have not been established.

Geriatric Use:

Geriatric use: no overall differences in safety of effectiveness have been observed in between elderly and younger patients.

Description:

Description: neomycin and polymyxin b sulfates, bacitracin zinc and hydrocortisone acetate ophthalmic ointment is a sterile antimicrobial and anti-inflammatory ointment for ophthalmic use. each gram contains: neomycin sulfate equivalent to 3.5 mg neomycin base, polymyxin b sulfate equivalent to 10,000 polymyxin b units, bacitracin zinc equivalent to 400 bacitracin units, hydrocortisone acetate 10 mg (1 %), in a white petrolatum and mineral oil base. bacitracin zinc is the zinc salt of bacitracin, a mixture of related cyclic polypeptides (mainly bacitracin a) produced by the growth of an organism of the licheniformis group of bacillus subtilis var tracy. it has a potency of not less than 40 bacitracin units per mg. the structural formula is: neomycin sulfate is the sulfate salt of neomycin b and c, which are produced by the growth of streptomyces fradiae waksman (fam. streptomycetaceae). it has a potency equivalent of not less than 600 μg of neomycin standard per mg, calculated on an anhydrous basis. the structural formulae are: polymyxin b sulfate is the sulfate salt of polymyxin b1 and b2, which are produced by the growth of bacillus polymyxa (prazmowski) migula (fam. bacillaceae). it has a potency of not less than 6,000 polymyxin b units per mg, calculated on an anhydrous basis. the structural formulae are: chemical structure chemical structure chemical structure

Clinical Pharmacology:

Clinical pharmacology: corticosteroids suppress the inflammatory response to a variety of agents and they probably delay or slow healing. since corticosteroids may inhibit the body's defense mechanism against infection, concomitant antimicrobial drugs may be used when this inhibition is considered to be clinically significant in a particular case. when a decision to administer both a corticosteroid and antimicrobials is made, the administration of such drugs in combination has the advantage of greater patient compliance and convenience, with the added assurance that the appropriate dosage of all drugs is administered. when each type of drug is in the same formulation, compatibility of ingredients is assured and the correct volume of drug is delivered and retained. the relative potency of corticosteroids depends on the molecular structure, concentration, and release from the vehicle. microbiology: the anti-infective components in neomycin and polymyxin b sulfates, bacitracin zinc and hy
drocortisone acetate ophthalmic ointment are included to provide action against specific organisms susceptible to it. neomycin sulfate and polymyxin b sulfate are active in vitro against susceptible strains of the following microorganisms: staphylococcus aureus , streptococci including streptococcus pneumoniae, escherichia coli, haemophilus influenzae, klebsiella/enterobacter species, neisseria species, and pseudomonas aeruginosa . the product does not provide adequate coverage against serratia marcescens (see indications and usage ).

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Carcinogenesis, mutagenesis, impairment of fertility: long-term studies in animals to evaluate carcinogenic or mutagenic potential have not been conducted with polymyxin b sulfate or bacitracin. treatment of cultured human lymphocytes in vitro with neomycin increased the frequency of chromosome aberrations at the highest concentrations (80 μg/ml) tested; however, the effects of neomycin on carcinogenesis and mutagenesis in humans are unknown. long-term studies in animals (rats, rabbits, mice) showed no evidence of carcinogenicity or mutagenicity attributable to oral administration of corticosteroids. long-term animal studies have not been performed to evaluate the carcinogenic potential of topical corticosteroids. studies to determine mutagenicity with hydrocortisone acetate have revealed negative results. polymyxin b has been reported to impair the motility of equine sperm, but its effects on male or female fertility are unknown. no adverse effects on male or female fertility, litt
er size, or survival were observed in rabbits given bacitracin zinc 100 gm/ton of diet. long-term animal studies have not been performed to evaluate the effect on fertility of topical corticosteroids.

How Supplied:

How supplied: neo-polycin® hc ophthalmic ointment is supplied in 3.5 g (1/8 oz) sterile tamper evident tube with ophthalmic tip. ndc 0574- 4144 -35 store at 20°-25°c (68°-77°f) [see usp controlled room temperature] neo-polycin® hc is a registered trademark of perrigo company

Information for Patients:

Information for patients: if inflammation or pain persists longer than 48 hours or becomes aggravated, the patient should be advised to discontinue use of the medication and consult a physician. this product is sterile when packaged. to prevent contamination, care should be taken to avoid touching the tip of the tube to eyelids or to any other surface. the use of this tube by more than one person may spread infection. keep out of the reach of children.

Package Label Principal Display Panel:

Package/label principal display panel - carton rx only ndc 0574- 4144 -35 sterile neo-polycin® hc neomycin and polymyxin b sulfates, bacitracin zinc, and hydrocortisone acetate ophthalmic ointment usp net wt 3.5 g (1/8 oz) the following image is a placeholder representing the product identifier that is either affixed or imprinted on the drug package label during the packaging operation. neo-polycin-carton serialization-template


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.